Because the mTOR inhibitor temsirolimus has been approved as a first-line drug to treat metastatic ccRCC, LTF downregulation may serve as a good biomarker to guide the medication of temsirolimus in clinics to treat metastatic ccRCC without PTEN mutation. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.